Related Experiment Video
Updated: Oct 22, 2025
06:20
Author Spotlight: Advancing VRL Diagnosis Using Cell-Free DNA Extraction from Vitreous Humor
Published on: January 12, 2024
2.2K
Vitreoretinal Lymphoma
Bianka Sobolewska1, Soon-Phaik Chee2,3,4,5, Fatma Zaguia6
1Center of Ophthalmology, University of Tuebingen, 72076 Tuebingen, Germany.
Cancers
|August 27, 2021
Summary
Vitreoretinal lymphoma (VRL), a rare aggressive cancer, often progresses to central nervous system lymphoma. Early diagnosis and treatment are crucial for managing this challenging ocular and neurological condition.
Area of Science:
- Ophthalmology
- Neurology
- Oncology
Background:
- Vitreoretinal lymphoma (VRL) is a rare subtype of primary central nervous system lymphoma (PCNSL).
- VRL primarily affects the retina and vitreous, potentially involving the optic nerve.
- The disease course is aggressive, with a high risk of progression to CNS lymphoma.
Purpose of the Study:
- To highlight the diagnostic challenges of VRL, often presenting as nonspecific uveitis.
- To review current treatment strategies for VRL, particularly in cases of bilateral involvement without CNS disease.
- To emphasize the need for further research into prophylactic systemic therapies to prevent CNS progression.
Main Methods:
- Diagnosis relies on anterior chamber or vitreous aspirate biopsy.
- Treatment considerations include intravitreal chemotherapy (methotrexate, rituximab), systemic high-dose methotrexate, or radiotherapy.
- The study reviews existing literature and clinical observations regarding VRL management.
Main Results:
- VRL diagnosis is difficult due to overlapping symptoms with chronic uveitis.
- Up to 90% of VRL patients develop CNS lymphoma within a year.
- No established treatment protocol exists for bilateral VRL without CNS involvement.
Conclusions:
- VRL is an aggressive malignancy requiring prompt diagnosis and management.
- Intravitreal chemotherapy is a suggested treatment for limited VRL.
- Further research is essential to confirm the efficacy of systemic therapy in preventing CNS involvement.
